National Center for
5HZ9: Human Fabp3 In Complex With 6-chloro-2-methyl-4-phenyl-quinoline-3- Carboxylic Acid
Bioorg. Med. Chem. Lett. (2016) 26 p.5092-5097
Dual inhibition of fatty acid binding proteins 4 and 5 (FABP4 and FABP5) is expected to provide beneficial effects on a number of metabolic parameters such as insulin sensitivity and blood glucose levels and should protect against atherosclerosis. Starting from a FABP4 selective focused screening hit, biostructure information was used to modulate the selectivity profile in the desired way and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. With very good pharmacokinetic properties and no major safety alerts, compound 12 was identified as a suitable tool compound for further in vivo investigations.